Key result
A rapid and simple UPLC-MS/MS method was successfully developed and validated to quantify plasma concentrations of candesartan (mean 77.8 ng/mL) and olmesartan (mean 425 ng/mL) in hypertensive patients.
A rapid and simple UPLC-MS/MS method using protein precipitation was successfully developed and validated to measure plasma candesartan and olmesartan concentrations for pharmacokinetic studies.
Validated assay enables ARB plasma quantification in research; leaves open clinical TDM utility pending prospective studies.
> 0.99) in the concentration range of 2-500 ng/mL for candesartan and 5-2,500 ng/mL for olmesartan. Accuracies were 86.70-108.8% for candesartan and 87.87-112.6% for olmesartan. These methods were able to successfully measure plasma candesartan or olmesartan concentrations in hypertensive patients. This study can be used for pharmacokinetic studies of candesartan or olmesartan in humans.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2021) studied Hypertension (n=29). Candesartan or Olmesartan was evaluated on Plasma concentration of candesartan or olmesartan at steady-state. A rapid and simple UPLC-MS/MS method was successfully developed and validated to quantify plasma concentrations of candesartan (mean 77.8 ng/mL) and olmesartan (mean 425 ng/mL) in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: